Its Left Atrial Appendage Closure (LAAC) device – Watchman – has gained market share, driven by a higher physician utilization rate, bolstering its overall revenue growth. The S&P500 has now entered near bear market territory with rising concerns of slowing economic growth given the high inflation, Fed action, and supply chain disruptions. We estimate Boston Scientific’s valuation to be $47 per share, reflecting a 25% upside from its current market price of $37, implying that investors are likely to be better off buying BSX stock in the recent dip for solid gains in the long-term.